Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: John A Shepherd, PhD
- Phone Number: 808-440-5234
- Email: johnshep@hawaii.edu
Study Contact Backup
- Name: Leila Kazemi
- Phone Number: 808-440-5231
- Email: lkazemi@hawaii.edu
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- H. Lee Moffitt Cancer Center & Research Institute, Inc.
-
Contact:
- Emily Research Services Project Coordinator
- Phone Number: 813-745-5501
- Email: emily.amato@moffitt.org
-
Principal Investigator:
- Bethany L Niell, MD
-
Principal Investigator:
- Dana K Ataya, MD
-
-
Hawaii
-
Hilo, Hawaii, United States, 96720
- Recruiting
- Hawaii Radiology Associates, LTD (East Hawaii Women's Imaging Center)
-
Contact:
- Scott Grosskreutz, MD
- Phone Number: 808-935-1825
-
Principal Investigator:
- Scott Grosskreutz, MD
-
Honolulu, Hawaii, United States, 96822
- Recruiting
- The Queen's Medical Center
-
Contact:
- Richmond Clinical Research Associate
- Phone Number: 808-691-7609
- Email: riwong@queens.org
-
Principal Investigator:
- Todd Seto, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Had a recent diagnostic mammogram with a BI-RADS diagnostic score 4 or 5 assigned by a radiologist (BIRADS are standardized mammography assessment categories: 4 is for "Suspicious abnormality", 5 is for "Highly suggestive of malignancy".
- Have not had biopsy
Exclusion Criteria:
- Pregnant or breast feeding
- History of breast cancer or a mastectomy (removal of the breast) with Systemic Therapy (ex. Chemotherapy, hormones and hormone inhibitors, etc.).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantify biological composition of lesions
Time Frame: Baseline
|
Quantify the biological composition (lipid/water/protein) of suspicious lesions.
|
Baseline
|
|
Quantify morphology of lesions
Time Frame: Baseline
|
Quantify morphology/texture (radiomics) of suspicious lesions.
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of radiologists' image interpretations with and without q3CB signatures
Time Frame: Baseline
|
Difference in AUC between the "1st read" and "2nd read" image interpretations.
In the "1st read," they will be provided with the FFDM/DBT images and in the "2nd read," they will also be provided with the ncCEM q3CB composition and radiomics signature (likelihood of malignancy).
|
Baseline
|
|
Sensitivity and Specificity of readers' responses for the BI-RADs assessment categories
Time Frame: Baseline
|
Sensitivity and specificity values will be calculated: a BI-RADS assessment of 4a or higher (i.e., 4a, 4b, 4c, and 5) defined a positive call for cancer diagnosis and, conversely, a BI-RADS assessment of 3 or lower (i.e., 3, 2, and 1) defined a negative call for cancer diagnosis.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: John A Shepherd, PhD, University of Hawaii Cancer Research Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHEPHERD-2021-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.